Myelodysplastic Syndromes--Many New Drugs, Little Therapeutic Progress

Tefferi, Ayalew
November 2010
Mayo Clinic Proceedings;Nov2010, Vol. 85 Issue 11, p1042
Academic Journal
In this article, the author discusses the myelodysplastic syndromes (MDS) which constitute a form of blood cancer that primarily affects the elderly and characterized by anemia and high risk of leukemic transformation. The author is critical on the establishment of a robust Mayo Clinic health record system which published several retrospective studies including those in MDS. The author also investigated the recommendations for the use of iron chelation therapy for MDS.


Related Articles

  • Iron chelation therapy in myelodysplastic syndromes. Perpich, John; Blamble, Deborah // Hem/Onc Today;7/25/2009, Vol. 10 Issue 14, p6 

    The article presents information on a study which examined the therapeutic effect of iron chelation therapy on patients diagnosed with myelodysplastic syndromes.

  • Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan. Magalhães, S M M; Duarte, F B; Ribeiro, S C C; Borovik, C L; Lorand-Metze, I // Leukemia (08876924);Jan2000, Vol. 14 Issue 1, p214 

    Examines the development of sideroblastic anemia after treatment of chronic myeloid leukemia with busulfan. Relation between busulfan and myelodysplasia; Results of the bone marrow analysis; Possibility of a link between busulfan exposure and sideroblastic changes.

  • More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Hub, Y.O.; Jilani, I.; Estey, E.; Giles, F.; Kantarjian, H.; Albitar, M. // Leukemia (08876924);Nov2002, Vol. 16 Issue 11, p2249 

    Investigates the difference in apoptosis between refractory anemia with excess blasts in transformation, acute myeloid leukemia, and other categories of myelodysplastic syndrome. Analysis of fresh bone marrow samples using the Annexin V and mitochondrial potential assays; Measurement of...

  • Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Yazji, S.; Giles, F. J.; Tsimberidou, A-M.; Estey, E.H; Kantarjian, H. M.; O'Brien, S. A.; Kurzrock, R. // Leukemia (08876924);Nov2003, Vol. 17 Issue 11, p2101 

    The purpose of this study was to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndrome (MDS). Therapy consisted of ATG 40?mg/kg/day daily intravenously (i.v.) for 4 days; cyclosporine daily orally for 6 months with levels...

  • Ciclosporin.  // Reactions Weekly;1/5/2008, Issue 1183, p10 

    The article describes the case of a boy who developed acute lymphoblastic leukemia after receiving ciclosporin and prednisolone for myelodysplastic syndrome (MDS)-refractory anaemia. The patient initially experienced improvement in his condition after receiving ciclosporin and prednisolone for...

  • Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. Itzykson, R.; Ayari, S.; Vassilief, D.; Berger, E.; Slama, B.; Vey, N.; Suarez, F.; Beyne-Rauzy, O.; Guerci, A.; Cheze, S.; Thomas, X.; Stamatoullas, A.; Gardembas, M.; Bauduer, F.; Kolb, A.; Chaury, M. C.; Legros, L.; Damaj, G.; Chermat, F.; Dreyfus, F. // Leukemia (08876924);Apr2009, Vol. 23 Issue 4, p673 

    Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their erythroid response, particularly in patients...

  • Understanding Iron Overload. Ault, Patricia; Jones, Karen // Clinical Journal of Oncology Nursing;Oct2009, Vol. 13 Issue 5, p511 

    Patients receiving recurring blood transfusions as supportive therapy to treat chronic anemias, such as myelodysplastic syndromes, thalassemia, and sickle-cell disease, are at risk of iron accumulation. The clinical consequences of iron overload are progressive liver damage, cardiac disease, and...

  • Iron Chelation Therapy in Myelodysplastic Syndromes. Messa, Emanuela; Cilloni, Daniela; Saglio, Giuseppe // Advances in Hematology;2010, Vol. 2010, p1 

    Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic...

  • Management of Transfusional Chronic Iron Overload: Focus on Deferasirox. Pilo, Federica; Di Tucci, Anna Angela; Dessì, Laura; Angelucci, Emanuele // Clinical Medicine: Therapeutics;2009, Issue 1, p735 

    Most patients with hereditary or chronic acquired anemias are dependent on regular red cell transfusions. Untreated iron overload from transfusions is responsible for morbidity and mortality in patients with thalassemia major. However, clinical consequences of parenchymal iron overload have been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics